Treating childhood acute lymphoblastic leukemia without cranial irradiation.

PubWeight™: 7.95‹?› | Rank: Top 0.1%

🔗 View Article (PMC 2754320)

Published in N Engl J Med on June 25, 2009

Authors

Ching-Hon Pui1, Dario Campana, Deqing Pei, W Paul Bowman, John T Sandlund, Sue C Kaste, Raul C Ribeiro, Jeffrey E Rubnitz, Susana C Raimondi, Mihaela Onciu, Elaine Coustan-Smith, Larry E Kun, Sima Jeha, Cheng Cheng, Scott C Howard, Vickey Simmons, Amy Bayles, Monika L Metzger, James M Boyett, Wing Leung, Rupert Handgretinger, James R Downing, William E Evans, Mary V Relling

Author Affiliations

1: Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. ching-hon.pui@stjude.org

Associated clinical trials:

Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | NCT00137111

Articles citing this

(truncated to the top 100)

Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol (2012) 5.08

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41

Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol (2011) 4.34

The tumor lysis syndrome. N Engl J Med (2011) 4.29

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol (2010) 3.76

Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71

Acute lymphoblastic leukaemia. Lancet (2013) 3.44

The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82

Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med (2012) 2.60

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2012) 2.55

Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res (2011) 2.52

Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood (2010) 2.37

Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. N Engl J Med (2016) 2.36

The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet (2015) 2.34

Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24

Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20

Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA (2015) 2.20

Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncol (2015) 2.15

Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood (2012) 2.14

Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood (2012) 1.90

Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood (2011) 1.88

Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol (2015) 1.84

New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2011) 1.78

Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. J Clin Oncol (2013) 1.76

Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol (2013) 1.75

Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol (2015) 1.74

L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer (2010) 1.69

High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood (2011) 1.68

PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet (2012) 1.66

Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst (2012) 1.64

Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group. J Clin Oncol (2014) 1.63

Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol (2011) 1.60

Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies. Pediatr Blood Cancer (2011) 1.59

Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood (2015) 1.57

The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia (2010) 1.56

Challenging issues in pediatric oncology. Nat Rev Clin Oncol (2011) 1.56

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol (2010) 1.52

Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol (2010) 1.49

Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood (2010) 1.47

Cellular elements of the subarachnoid space promote ALL survival during chemotherapy. Leuk Res (2011) 1.46

Prognostic factors that increase the risk for reduced white matter volumes and deficits in attention and learning for survivors of childhood cancers. Pediatr Blood Cancer (2014) 1.45

Energy balance and fitness in adult survivors of childhood acute lymphoblastic leukemia. Blood (2015) 1.42

Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. J Natl Cancer Inst (2012) 1.41

Increased μ-Calpain Activity in Blasts of Common B-Precursor Childhood Acute Lymphoblastic Leukemia Correlates with Their Lower Susceptibility to Apoptosis. PLoS One (2015) 1.39

Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest (2012) 1.38

Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906. Pediatr Blood Cancer (2011) 1.33

A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol (2013) 1.32

Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol (2014) 1.31

Curing myeloma at last: defining criteria and providing the evidence. Blood (2014) 1.30

Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin Pharmacol (2011) 1.29

Temporal trends in cause-specific late mortality among 5-year survivors of childhood cancer. J Clin Oncol (2010) 1.27

PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics (2011) 1.27

Attention and working memory abilities in children treated for acute lymphoblastic leukemia. Cancer (2010) 1.26

Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007. J Clin Oncol (2012) 1.25

Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. J Clin Invest (2013) 1.19

Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood (2015) 1.19

Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol (2010) 1.16

Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther (2010) 1.15

Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol (2010) 1.14

Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group. J Clin Oncol (2010) 1.13

Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer (2012) 1.12

Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol (2014) 1.10

Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia (2012) 1.10

The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer (2011) 1.10

Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. J Clin Oncol (2013) 1.10

Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood (2015) 1.09

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. Blood (2015) 1.08

ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia (2011) 1.08

Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health. Expert Rev Hematol (2011) 1.07

Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells. PLoS Comput Biol (2010) 1.07

Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncol (2013) 1.07

Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia. Blood Cancer J (2013) 1.06

Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer (2012) 1.06

A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood (2014) 1.04

Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am (2014) 1.04

Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia: associations with physical performance and chemotherapy doses. Cancer (2011) 1.03

A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia (2010) 1.03

Historical trends in the use of radiation therapy for pediatric cancers: 1973-2008. Int J Radiat Oncol Biol Phys (2012) 1.02

Progress of minimal residual disease studies in childhood acute leukemia. Curr Hematol Malig Rep (2010) 1.02

NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat Genet (2015) 1.02

Mathematics intervention for prevention of neurocognitive deficits in childhood leukemia. Pediatr Blood Cancer (2011) 1.00

Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer (2012) 0.99

ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol (2012) 0.98

Biology of childhood acute lymphoblastic leukemia. Pediatr Clin North Am (2015) 0.97

Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia. Cancer (2013) 0.96

Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol (2013) 0.96

Marriage and parenthood among childhood cancer survivors: a report from the Italian AIEOP Off-Therapy Registry. Haematologica (2011) 0.95

A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia (2014) 0.95

IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan. Cancer Med (2013) 0.95

Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407. Pediatr Blood Cancer (2012) 0.93

Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: A systematic review. Neurosci Biobehav Rev (2015) 0.92

Evidence for age as a modifier of genetic associations for lipid levels. Ann Hum Genet (2011) 0.92

Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia - From the St. Jude Lifetime Cohort. Br J Haematol (2014) 0.92

Widespread osteonecrosis in children with leukemia revealed by whole-body MRI. Clin Orthop Relat Res (2012) 0.91

Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. Int J Data Min Bioinform (2011) 0.91

A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm. Clin Pharmacol Ther (2013) 0.91

Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica (2014) 0.90

Dexamethasone exposure and memory function in adult survivors of childhood acute lymphoblastic leukemia: A report from the SJLIFE cohort. Pediatr Blood Cancer (2013) 0.90

Articles cited by this

Chronic health conditions in adult survivors of childhood cancer. N Engl J Med (2006) 19.97

Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30

Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA (2007) 5.74

Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21

Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med (2003) 3.57

Acute lymphoblastic leukemia. N Engl J Med (1998) 3.15

Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood (2000) 3.13

Moving towards individualized medicine with pharmacogenomics. Nature (2004) 2.99

Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood (2000) 2.92

Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA (2003) 2.77

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood (2008) 2.68

Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood (2003) 2.65

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood (2006) 2.62

Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med (1998) 2.59

Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004. J Natl Cancer Inst (2008) 2.56

Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia (2000) 2.48

Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA (2007) 2.38

Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol (2008) 2.29

Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood (1999) 2.18

Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol (2008) 2.14

Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol (2005) 2.13

Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol (2003) 2.12

Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood (2002) 2.05

Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia (2000) 1.94

Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia. JAMA (2002) 1.93

Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood (2000) 1.89

Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood (2002) 1.68

Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia (2004) 1.65

Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood (1998) 1.60

Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 1.58

Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia (2000) 1.56

Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood (2007) 1.52

Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood (2006) 1.48

Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. J Clin Oncol (2007) 1.46

Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest (2005) 1.46

BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia (2002) 1.39

Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med (1993) 1.31

Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia (2000) 1.25

Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study. J Clin Oncol (2006) 1.17

Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). Br J Haematol (2004) 1.14

Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood (2003) 1.11

Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: experience of the Dutch Childhood Oncology Group. J Clin Oncol (2006) 1.02

Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group. Blood (2007) 1.01

Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups. J Clin Oncol (1997) 1.00

Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995. Leukemia (2000) 0.94

Pilot studies of species-specific chemotherapy of childhood acute lymphoblastic leukemia using genotype and immunophenotype. Leukemia (2000) 0.93

Effect of body position on ventricular CSF methotrexate concentration following intralumbar administration. J Clin Oncol (1995) 0.91

Effect of probenecid on ventricular cerebrospinal fluid methotrexate pharmacokinetics after intralumbar administration in nonhuman primates. Cancer Chemother Pharmacol (2001) 0.89

Articles by these authors

MicroRNA expression profiles classify human cancers. Nature (2005) 69.12

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83

Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54

BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89

Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol (2005) 9.76

Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25

Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61

Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol (2006) 6.92

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91

Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64

Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature (2011) 6.39

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood (2008) 5.49

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37

CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods (2011) 5.34

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22

A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02

JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 4.98

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89

Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89

Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88

Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82

Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood (2003) 4.54

T-helper-1-cell cytokines drive cancer into senescence. Nature (2013) 4.47

Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell (2009) 4.43

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35

Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol (2009) 4.20

Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16

Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood (2010) 4.00

Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood (2006) 3.91

Gene expression profiling of pediatric acute myelogenous leukemia. Blood (2004) 3.77